GLP-1 Claims Rose, Prompting Calls for New Coverage Strategies
As claim volumes climb, experts urge employers to view GLP-1 therapy as a core cardiometabolic health strategy.
Updated on Sept. 30, 2026 in Diabetes
Live Poll
Should employers prioritize long-term preventative health over reducing immediate pharmacy costs in their benefit plans?
GLP-1 drug claim volumes increased 24 percent over the past year in the United States, driving a new focus on how employer health plans manage these costs. Executives are now recommending that companies structure coverage around specific evidence-based criteria to better manage cardiometabolic risk.
Why it matters
High out-of-pocket costs remain a primary barrier to treatment adherence for employees managing complex health conditions. By integrating GLP-1 coverage into broader cardiometabolic strategies, employers may better address the rising volume of claims involving multiple comorbidities.
Insurance analysis shows a 24 percent annual increase in GLP-1 claims and reveals that 22 percent of high-cost claims involve simultaneous cancer and cardiovascular conditions. Data on second-opinion programs further shows that 50 percent of patients experience a change in diagnosis or treatment.
The players
Jennifer Collier
A Sun Life executive who has recommended that employers frame GLP-1 coverage as a cardiometabolic risk management strategy.
Sun Life
A major insurance company headquartered in Wellesley Hills, Massachusetts, that provides disability, life, and health insurance.
The details
Effective insurance plan design for GLP-1s requires establishing evidence-based eligibility criteria and structured support programs. Because comorbidities like cancer, kidney disease, and orthopedic conditions frequently overlap in high-cost claims, administrators are shifting focus toward cost-sharing models that address total patient risk. This approach aims to reduce the financial burden that often leads to non-adherence for employees managing chronic conditions.
Timeline
September 30, 2026: Sun Life released strategic guidance regarding GLP-1 coverage.
Health Landscape
The push for integrated GLP-1 coverage marks a departure from traditional, siloed pharmacy benefit management. It reflects a broader healthcare evolution toward treating complex cardiometabolic risk rather than focusing on single-condition interventions.
If you are considering GLP-1 therapy, check your specific employer plan's eligibility criteria for structured support programs. It is worth discussing with your doctor how your treatment plan coordinates with the management of any other ongoing health conditions you may have.
The takeaway
Healthcare data highlights that half of patients who seek an expert second opinion find their diagnosis or treatment path changes. When navigating complex treatment options, consider asking your physician about the necessity of a second opinion to confirm your current diagnostic path.
Further reading
For more on management approaches, visit the Diabetes section.
Source note: This article includes information reported by Insurance Business.
Live Poll
Should employers prioritize long-term preventative health over reducing immediate pharmacy costs in their benefit plans?
